Increased plasma conc w/ inhibitors of CYP3A4 (eg, itraconazole, ketoconazole, voriconazole, posaconazole, HIV PIs, clarithromycin, telithromycin, nefazodone, grapefruit juice; diltiazem, erythromycin, fluconazole), P-gp (eg, ciclosporin, verapamil) & CYP2D6 (eg, paroxetine) inhibitors. Decreased steady-state conc w/ CYP3A4 inducers (eg, rifampicin, phenytoin, phenobarb, carbamazepine, St. John's wort). Increased plasma conc of P-gp or CYP3A4 substrates (eg, simvastatin, lovastatin, atorvastatin; ciclosporin, tacrolimus, sirolimus, everolimus); digoxin. Increased exposure to metoprolol or other CYP2D6 substrates (eg, propafenone & flecainide or to a lesser extent, TCAs & antipsychotics); metformin & other OCT2 substrates (eg, pindolol & varenicline). CYP2B6 substrates (eg, bupropion, efavirenz, cyclophosphamide). Increased possible risk of ventricular arrhythmias w/ antihistamines (eg, terfenadine, astemizole, mizolastine), antiarrhythmics (eg, quinidine, disopyramide, procainamide), erythromycin & TCAs (eg, imipramine, doxepin, amitriptyline).